Amgen Inc. (AMGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN)

AMGN 336.00

-0.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JGoren who wrote (628)	9/9/1998 7:37:00 AM
From: Dr. John M. de Castro	Read Replies (2) of 1906

Leptin is a dud. I was at the International Congress on Obesity in Paris where Amgen presented the results of the Leptin obesity clinical trial. The results are lousy. The only responses are with the highest doses (if my memory serves me it was .3 mg/kg 3 X per day, a very large dose) and only in a few subjects. To make matters worse, there was a high rate of injection site adverse events. They also presented some puzzling data. 30% of the subjects in the dose ranging pharmacokinetics study developed antibodies to the injected Leptin. I asked a number of people how this could happen with a recombinant human molecule and received nothing but shoulder shrugs. I was very busy at the meeting and never saw any of the Amgen people and didn't have a chance to talk to them. But, it was clear from the data why there was no press release. If you're looking for a pop from the Leptin results, forget it. This is not the next major drug for Amgen. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next